Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica Pittenger"'
Autor:
Elizabeth A. Mittendorf, Shom Goel, Eric P. Winer, Tianyu Li, Khanh T. Do, Geoffrey I. Shapiro, Leilani Anderson, Jessica Pittenger, Lorenzo Trippa, Sara M. Tolaney, Kamaneh Montazeri, Aditya Bardia, Chelsea Andrews, Christina I. Herold
Publikováno v:
Cancer Research. 80:P3-14
Background: Immune checkpoint inhibitors (ICI), such as those targeting the PD-1/PD-L1 axis, have shown modest activity as monotherapy in both HR+ MBC and MOC. Strategies to improve ICI for these diseases are under investigation. In mouse models, CDK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d01dfb9536fd50d76edbceb54150f7f
https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03
https://doi.org/10.1158/1538-7445.sabcs19-p3-14-03
Autor:
Shom Goel, Heather Ann Brauer, Yuqi Ren, Kara Gorman, Wafa Osmani, Jessica Pittenger, Chelsea Andrews, Edward T Richardson, Elizabeth A Mittendorf, MD PhD, Eric P Winer, Stuart Schnitt, Sara M Tolaney
Publikováno v:
Cancer Research. 80:P4-06
Introduction: TNBCs show marked heterogeneity in their spectrum of genomic alterations, patterns of gene expression, proteomic profiles, and immune microenvironments. Although TNBC heterogeneity has been characterized at each of these levels individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f8a5c476a4eb628374323ecfb0fb0b5
https://doi.org/10.1158/1538-7445.sabcs19-p4-06-01
https://doi.org/10.1158/1538-7445.sabcs19-p4-06-01
Autor:
Jessica Pittenger, Tanya Keenan, Ines Vaz-Luis, Natalie Faye Sinclair, Beth Overmoyer, Nan Lin, Edward T. Richardson, Lorenzo Trippa, Ian E. Krop, Ann H. Partridge, Gerburg M. Wulf, Eliezer M. Van Allen, Sara M. Tolaney, Eric P. Winer, Laura Spring, Tianyu Li, Elizabeth A. Mittendorf, Chelsea Andrews, Deborah A. Dillon, Romualdo Barroso-Sousa
Publikováno v:
JAMA Oncol
IMPORTANCE: Prior studies have shown that only a small proportion of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b538fa4e9d58620050e30dc5c8ad3cb
https://pubmed.ncbi.nlm.nih.gov/32880602
https://pubmed.ncbi.nlm.nih.gov/32880602
Autor:
Chelsea Andrews, Tanya Keenan, Jiani Hu, Sara M. Tolaney, Eric P. Winer, Laura Spring, Jessica Pittenger, Beth Overmoyer, Edward T. Richardson, Gerburg M. Wulf, Nan Lin, Deborah A. Dillon, Ines Maria Vaz Duarte Luis, Ann H. Partridge, Romualdo Barroso-Sousa, Elizabeth A. Mittendorf, Ian E. Krop, Lorenzo Trippa, Natalie Faye Sinclair, Eliezer VanAllen
Publikováno v:
Journal of Clinical Oncology. 37:1004-1004
1004 Background: Studies of checkpoint inhibitor monotherapy show only modest activity in HR+ MBC. We report data from the first randomized study comparing E plus P versus E alone in HR+/HER2- MBC. Methods: Eligible patients (pts) had HR+/HER2- MBC,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e2b088845565a0f0b26101261e1fb63
https://doi.org/10.1200/jco.2019.37.15_suppl.1004
https://doi.org/10.1200/jco.2019.37.15_suppl.1004